Outcomes
MRD
MINIMAL RESIDUAL DISEASE, MYELOMA
The primary end point was the proportion of patients achieving an overall response, including stringent complete response (sCR), complete response (CR), very good partial response (VGPR), and partial response (PR). Clinical responses were assessed according to the International Myeloma Working Group criteria.Minimal residual disease (MRD) was monitored according to the EuroFlow protocol.